Elanco Animal Health Incorporated
Elanco Animal Health Incorporated Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Elanco expects continued momentum with high single-digit to low double-digit growth in U.S. - Full-year 2026 organic constant currency revenue growth is expected at 5% to 7%, up from a prior outlook of 4% to 6%. - Adjusted EBITDA guidance for 2026 is raised by $20 million to a range of $975 million to $1.005 billion, representing about 10% growth at midpoint. - Adjusted EPS guidance is increased by $0.03 to a range of $1.03 to $1.09, reflecting 13% growth at midpoint. - Q2 2026 revenue forecast is $1.3 billion to $1.325 billion with organic constant currency growth of 4% to 6%. - Operating expenses expected to increase about 8% in constant currency due to launch investments. - U.S.
From Elanco Animal Health Incorporated's Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- Elanco expects continued momentum with high single-digit to low double-digit growth in U.S. Pet Health in H2 2026, driven by innovation launches like Zenrelia, Credelio Quattro, and Befrena.
- The full year 2026 U.S. Pet Health business is forecasted to deliver at least high single-digit revenue growth.
- Farm Animal segment shows durable trends with continued growth; poultry growing 3% annually, dairy gaining momentum, and cattle herd rebuild supporting volume increases.
- International derm market (e.g., Zenrelia) is growing double digits, faster than U.S., with expansion into 44 countries and more share gains expected.
- Global innovation pipeline targets 5-6 new blockbusters by 2031, unlocking over $2 billion in peak sales potential.
- Overall company revenue guidance raised to 5-7% organic constant currency growth in 2026.
2 more points from Elanco Animal Health Incorporated's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Elanco Animal Health Incorporated said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital allocation priorities focus primarily on organic growth investments and debt reduction.
- Small tuck-in M&A opportunities will continue but remain disciplined so as not to derail deleveraging progress.
- Flexibility for more capital deployment and shareholder returns anticipated when net leverage falls below 3x around 2027.
- Continued investments expected in innovation product launches, marketing (including DTC), and R&D to fuel growth.
2 more points from Elanco Animal Health Incorporated's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Elanco Animal Health Incorporated said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Elanco Animal Health Incorporated's call on order book
Create a free account to keep reading this call
Continue your research
Others in Pharmaceuticals this season
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
- Royalty Pharma plc (Q2 FY26)
Royalty Pharma plc Q2 FY26 quarterly results analysis. Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven b
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Elanco Animal Health Incorporated and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Elanco Animal Health Incorporated Q2 FY26 results?
- Elanco expects continued momentum with high single-digit to low double-digit growth in U.S. - Full-year 2026 organic constant currency revenue growth is expected at 5% to 7%, up from a prior outlook of 4% to 6%. - Adjusted EBITDA guidance for 2026 is raised by $20 million to a range of $975 million to $1.005 billion, representing about 10% growth at midpoint. - Adjusted EPS guidance is increased by $0.03 to a range of $1.03 to $1.09, reflecting 13% growth at midpoint. - Q2 2026 revenue forecast is $1.3 billion to $1.325 billion with organic constant currency growth of 4% to 6%. - Operating expenses expected to increase about 8% in constant currency due to launch investments. - U.S.
What is Elanco Animal Health Incorporated share price analysis?
Elanco Animal Health Incorporated currently shows a below-average growth signal. The stock trades at a P/E of 18.8 with a market cap of $11,977. Investors should review the full earnings analysis for detailed insights.
Keep Elanco Animal Health Incorporated on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.